Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently offered insights on. Cramer highlighted the company’s ...

Abbott announced today that it agreed to acquire diagnostics maker Exact Sciences for approximately $21 billion.

The deal will allow Abbott — which makes continuous glucose monitors and other products — to enter the cancer testing space.

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and ...

After the deal closes, Abbott says Exact Sciences will maintain its presence in Madison. Exact Sciences CEO Kevin Conroy will ...

Now, it’s worth noting Stock Advisor’s total average return is 1,013% — a market-crushing outperformance compared to 188 % ...

Abbott will acquire Madison-based cancer diagnostics company Exact Sciences in a $21 billion deal, expanding its global diagnostics portfolio.

Exact Sciences shareholders will receive $105 per common share as part of the deal, which is expected to close in the second quarter of 2026.

The company shared new real-world findings for Aveir DR at the Asia Pacific Heart Rhythm Society (APHRS). These add to strong ...